bpc-157 clinical trials human safety – No Proof Required! | Office for Science and Society The Hidden Risks of BPC‑157:

The standard protocol combines daily BPC-157 at 0.25 to 0.5 mg with TB-500 at 5 mg weekly during the loading phase, typically split into 2.5 mg doses twice weekly

Together, they address both sides of gut damage repairing the structure and restoring balanceoffering a comprehensive approach for conditions involving chronic inflammation and intestinal injury

Studies on mitochondrial function and cellular respiration

D+Q: Senolytic therapy including the combination of Dasatinib and Quercetin

Doses as high as 2 mg (2,000 g) daily by mouth or 1 mg monthly by intramuscular (IM) injection have been used to treat pernicious anemia without significant side effects (136)